Amicus Therapeutics (NASDAQ:FOLD) has received an average recommendation of “Buy” from the ten analysts that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $20.25.
A number of equities analysts have recently issued reports on FOLD shares. ValuEngine upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. BidaskClub upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, January 15th. Leerink Swann upped their target price on shares of Amicus Therapeutics from $20.00 to $24.00 and gave the stock an “outperform” rating in a research report on Thursday, February 8th. Zacks Investment Research lowered shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, March 13th. Finally, Cowen reiterated a “buy” rating and set a $22.00 target price on shares of Amicus Therapeutics in a research report on Wednesday, January 10th.
In related news, CFO William D. Baird III sold 10,000 shares of the stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $14.26, for a total value of $142,600.00. Following the transaction, the chief financial officer now directly owns 127,662 shares in the company, valued at $1,820,460.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Bradley L. Campbell sold 32,500 shares of the stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $15.92, for a total transaction of $517,400.00. Following the completion of the transaction, the chief operating officer now owns 186,600 shares in the company, valued at $2,970,672. The disclosure for this sale can be found here. Insiders sold 89,399 shares of company stock worth $1,388,425 over the last 90 days. 3.40% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in FOLD. BlackRock Inc. increased its stake in Amicus Therapeutics by 2.6% in the fourth quarter. BlackRock Inc. now owns 13,712,097 shares of the biopharmaceutical company’s stock valued at $197,317,000 after purchasing an additional 342,861 shares in the last quarter. Franklin Resources Inc. increased its stake in Amicus Therapeutics by 12.3% in the fourth quarter. Franklin Resources Inc. now owns 3,718,899 shares of the biopharmaceutical company’s stock valued at $53,515,000 after purchasing an additional 406,499 shares in the last quarter. Sectoral Asset Management Inc increased its stake in Amicus Therapeutics by 18.1% in the fourth quarter. Sectoral Asset Management Inc now owns 2,850,769 shares of the biopharmaceutical company’s stock valued at $41,023,000 after purchasing an additional 437,899 shares in the last quarter. Victory Capital Management Inc. increased its stake in Amicus Therapeutics by 6.1% in the fourth quarter. Victory Capital Management Inc. now owns 2,644,924 shares of the biopharmaceutical company’s stock valued at $38,061,000 after purchasing an additional 151,755 shares in the last quarter. Finally, Carillon Tower Advisers Inc. bought a new stake in Amicus Therapeutics in the fourth quarter valued at approximately $26,756,000.
Shares of FOLD stock opened at $14.37 on Friday. Amicus Therapeutics has a 1 year low of $6.41 and a 1 year high of $17.40. The company has a market cap of $2,736.09, a PE ratio of -4.92 and a beta of 1.46. The company has a current ratio of 5.60, a quick ratio of 5.53 and a debt-to-equity ratio of 0.47.
Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.11). Amicus Therapeutics had a negative return on equity of 71.06% and a negative net margin of 769.03%. The company had revenue of $14.73 million for the quarter, compared to analyst estimates of $14.50 million. research analysts predict that Amicus Therapeutics will post -1.36 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/15/amicus-therapeutics-fold-receives-consensus-rating-of-buy-from-analysts.html.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.